Exercise Intolerance in Pulmonary Arterial Hypertension. The Role of Cardiopulmonary Exercise Testing

2015 ◽  
Vol 12 (4) ◽  
pp. 604-612 ◽  
Author(s):  
J. Alberto Neder ◽  
Roberta P. Ramos ◽  
Jaquelina S. Ota-Arakaki ◽  
Daniel M. Hirai ◽  
Christine L. D’Arsigny ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Exercise Testing ◽  
Cardiopulmonary Exercise Testing ◽  
Exercise Intolerance ◽  
Cardiopulmonary Exercise ◽  
Pulmonary Arterial

scholarly journals Detection of Exercise-Induced Pulmonary Arterial Hypertension by Cardiopulmonary Exercise Testing

2012 ◽  
Vol 35 (9) ◽  
pp. 548-553 ◽  
Author(s):  
Martin Schwaiblmair ◽  
Christian Faul ◽  
Wolfgang von Scheidt ◽  
Thomas M. Berghaus
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Exercise Testing ◽  
Cardiopulmonary Exercise Testing ◽  
Cardiopulmonary Exercise ◽  
Pulmonary Arterial ◽  
Exercise Induced

scholarly journals 150 Incremental value of cardiopulmonary exercise testing in intermediate-risk pulmonary arterial hypertension

2021 ◽  
Vol 23 (Supplement_G) ◽  
Author(s):  
Roberto Badagliacca ◽  
Franz Rischard ◽  
Francesco Lo Giudice ◽  
Luke Howard ◽  
Silvia Papa ◽  
...  
Keyword(s):  
Risk Assessment ◽  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Exercise Testing ◽  
Prognostic Model ◽  
Cardiopulmonary Exercise Testing ◽  
Intermediate Risk ◽  
Cardiopulmonary Exercise ◽  
Pulmonary Arterial

Abstract Aims Risk assessment in pulmonary arterial hypertension (PAH) is essential for prognostication. However, the majority of patients end-up in an intermediate risk status despite targeted-therapy, offering insufficient guidance in clinical practice. The added value of cardiopulmonary exercise testing (CPET) in this setting remains undefined. Methods and results Two independent cohorts with idiopathic PAH at intermediate risk were used to develop (n = 124) and externally validate (n = 143) the prognostic model. Risk assessment was based on the simplified version of the ESC/ERS guidelines score. The same definition of clinical worsening (CW) was used for both cohorts. Discrimination and calibration were assessed. Seventy-four derivation cohort patients experienced CW (51.2%) during a median of 34 months. Stroke volume index (SVI) and 6-min walk-distance (6MWD) were independent predictors of CW. With addition of CPET variables, SVI and VO2 peak independently improved the power of the prognostic model, determined by the integrated discrimination integral (IDI) index. ROC-derived cut-off values for SVI and VO2 peak were 34 and 14 ml/kg/min, respectively. Forty-eight validation cohort patients experienced CW (33.5%) during a median of 27 months follow-up. Different combinations of cut-off values of SVI and VO2 peak defined three meaningful groups showing good discrimination and calibration. The event-free survival rates at 1, 2, and 3 years were, respectively, 96%, 89%, and 89% for high SVI/high VO2 peak combination; 85%, 73%, and 61% for high SVI/low VO2 peak; and 80%, 70%, and 56% for low SVI/low VO2 peak. Conclusions Combinations of VO2 peak and SVI during follow-up is important in the prognostication of intermediate-risk prevalent patients with idiopathic PAH.

The added value of cardiopulmonary exercise testing in the follow-up of pulmonary arterial hypertension

2019 ◽  
Vol 38 (3) ◽  
pp. 306-314 ◽  
Author(s):  
Roberto Badagliacca ◽  
Silvia Papa ◽  
Roberto Poscia ◽  
Gabriele Valli ◽  
Beatrice Pezzuto ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Exercise Testing ◽  
Cardiopulmonary Exercise Testing ◽  
Added Value ◽  
Cardiopulmonary Exercise ◽  
Pulmonary Arterial

Cardiopulmonary exercise testing for detecting pulmonary arterial hypertension in systemic sclerosis

Heart ◽  
2017 ◽  
Vol 103 (10) ◽  
pp. 774-782 ◽  
Author(s):  
Daniel Dumitrescu ◽  
Christian Nagel ◽  
Gabor Kovacs ◽  
Tom Bollmann ◽  
Michael Halank ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Exercise Testing ◽  
Cardiopulmonary Exercise Testing ◽  
Cardiopulmonary Exercise ◽  
Pulmonary Arterial

Signal-morphology impedance cardiography during incremental cardiopulmonary exercise testing in pulmonary arterial hypertension

2012 ◽  
Vol 32 (5) ◽  
pp. 343-352 ◽  
Author(s):  
Eloara M. Ferreira ◽  
Jaquelina S. Ota- Arakaki ◽  
Priscila B. Barbosa ◽  
Ana Cristina B. Siqueira ◽  
Daniela M. Bravo ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Exercise Testing ◽  
Impedance Cardiography ◽  
Cardiopulmonary Exercise Testing ◽  
Cardiopulmonary Exercise ◽  
Pulmonary Arterial

scholarly journals Cardiopulmonary Exercise Testing Is an Accurate Tool for the Diagnosis of Pulmonary Arterial Hypertension in Scleroderma Related Diseases

2021 ◽  
Vol 14 (4) ◽  
pp. 342
Author(s):  
Mattia Bellan ◽  
Ailia Giubertoni ◽  
Cristina Piccinino ◽  
Mariachiara Buffa ◽  
Debora Cromi ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Exercise Testing ◽  
Diagnostic Performance ◽  
Cardiopulmonary Exercise Testing ◽  
Laboratory Data ◽  
Connective Tissue Diseases ◽  
Cardiopulmonary Exercise ◽  
Pulmonary Arterial ◽  
End Tidal

The early diagnosis of pulmonary arterial hypertension (PAH) is a major determinant of prognosis in patients affected by connective tissue diseases (CTDs) complicated by PAH. In the present paper we investigated the diagnostic accuracy of cardiopulmonary exercise testing (CPET) in this specific setting. We recorded clinical and laboratory data of 131 patients who underwent a CPET at a pulmonary hypertension clinic. Out of them, 112 (85.5%) had a diagnosis of CTDs; 8 (6.1%) received a diagnosis of CTDs-PAH and 11 (8.4%) were affected PH of different etiology. Among CPET parameters the following parameters showed the best diagnostic performance for PAH: peak volume of oxygen uptake (VO2; AUC: 0.845, CI95% 0.767–0.904), ratio between ventilation and volume of exhaled carbon dioxide (VE/VCO2 slope; AUC: 0.888, CI95%: 0.817–0.938) and end-tidal partial pressures (PetCO2; AUC: 0.792, CI95%: 0.709–0.861). These parameters were comparable among CTDs-PAH and PH of different etiology. The diagnostic performance was even improved by creating a composite score which included all the three parameters identified. In conclusion, CPET is a very promising tool for the stratification of risk of PAH among CTDs patients; the use of composite measures may improve diagnostic performance.

Sign in / Sign up

Export Citation Format

Share Document